Eyenovia Stock Price, News & Analysis (NASDAQ:EYEN) $1.42 -0.04 (-2.74%) (As of 11/29/2023 ET) Add Compare Share Share Today's Range$1.40▼$1.5250-Day Range$1.08▼$1.7252-Week Range$1.05▼$5.85Volume320,143 shsAverage Volume316,265 shsMarket Capitalization$62.65 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Eyenovia MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside604.2% Upside$10.00 Price TargetShort InterestBearish4.44% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.29Based on 3 Articles This WeekInsider TradingAcquiring Shares$12,411 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.68) to ($0.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.84 out of 5 starsMedical Sector750th out of 949 stocksPharmaceutical Preparations Industry365th out of 443 stocks 3.5 Analyst's Opinion Consensus RatingEyenovia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Eyenovia has a forecasted upside of 604.2% from its current price of $1.42.Amount of Analyst CoverageEyenovia has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.44% of the outstanding shares of Eyenovia have been sold short.Short Interest Ratio / Days to CoverEyenovia has a short interest ratio ("days to cover") of 7.4.Change versus previous monthShort interest in Eyenovia has recently increased by 12.00%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEyenovia does not currently pay a dividend.Dividend GrowthEyenovia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EYEN. Previous Next 2.4 News and Social Media Coverage News SentimentEyenovia has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eyenovia this week, compared to 1 article on an average week.Search Interest2 people have searched for EYEN on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Eyenovia to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eyenovia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,411.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.80% of the stock of Eyenovia is held by insiders.Percentage Held by InstitutionsOnly 16.66% of the stock of Eyenovia is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Eyenovia are expected to decrease in the coming year, from ($0.68) to ($0.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eyenovia is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eyenovia is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEyenovia has a P/B Ratio of 3.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Eyenovia Stock (NASDAQ:EYEN)Eyenovia, Inc., a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi in rest of Asia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.Read More EYEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EYEN Stock News HeadlinesNovember 23, 2023 | finanznachrichten.deEyenovia, Inc.: Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 16, 2023 | uk.finance.yahoo.comEyenovia, Inc. (EYEN) stock price, news, quote & history – Yahoo FinanceNovember 30, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 14, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Arcellx Inc (ACLX), Clearside Biomedical (CLSD)November 14, 2023 | finance.yahoo.comEyenovia, Inc. (NASDAQ:EYEN) Q3 2023 Earnings Call TranscriptNovember 13, 2023 | msn.comEyenovia GAAP EPS of -$0.18 in-line, revenue of $1.19M beats by $1.03MNovember 13, 2023 | finance.yahoo.comEyenovia Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 9, 2023 | finance.yahoo.com4 Biotech Stocks Likely to Outpace Q3 Earnings EstimatesNovember 30, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!November 6, 2023 | finance.yahoo.comEyenovia to Report Third Quarter 2023 Results on Monday, November 13November 2, 2023 | msn.comWilliam Blair Initiates Coverage of Eyenovia (EYEN) with Outperform RecommendationNovember 2, 2023 | finance.yahoo.comEyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial ProductionNovember 1, 2023 | markets.businessinsider.comEyenovia's Stock Is Soaring Today - Here's WhyNovember 1, 2023 | benzinga.comEyenovia Stock (NASDAQ:EYEN), Analyst Ratings, Price Targets, PredictionsOctober 30, 2023 | insidermonkey.comBillionaire Marc Lasry’s Top 10 Stock PicksOctober 30, 2023 | finance.yahoo.comEyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) ProgramOctober 18, 2023 | msn.comBrookline Capital Initiates Coverage of Eyenovia (EYEN) with Buy RecommendationOctober 9, 2023 | finance.yahoo.comEyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®September 21, 2023 | finance.yahoo.comEyenovia to Participate in Panel Discussion at Cantor Global Healthcare ConferenceSeptember 7, 2023 | finance.yahoo.comEyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment ConferenceAugust 28, 2023 | msn.comEyenovia: It Is Now Time To See Positive Results In Their Marketing EffortsAugust 24, 2023 | finance.yahoo.comEyenovia Announces $12 Million Registered Direct OfferingAugust 18, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Eyenovia (EYEN)August 16, 2023 | msn.comEyenovia acquires US licencing rights for Formosa’s topical eye steroidAugust 16, 2023 | markets.businessinsider.comFormosa Pharma: Eyenovia Obtains U.S. Rights For Commercialization Of APP13007August 16, 2023 | finance.yahoo.comEyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa PharmaceuticalsAugust 16, 2023 | prnewswire.comFormosa Pharmaceuticals Announces Licensing Agreement with Eyenovia, Inc., for the Commercialization of APP13007 for the Treatment of Inflammation and Pain Following Ocular SurgerySee More Headlines Receive EYEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eyenovia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today11/30/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYEN CUSIPN/A CIK1682639 Webwww.eyenoviabio.com Phone(917) 289-1117FaxN/AEmployees41Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$12.00 Low Stock Price Target$8.00 Potential Upside/Downside+604.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,010,000.00 Net MarginsN/A Pretax Margin-2,541,699.75% Return on Equity-171.30% Return on Assets-81.62% Debt Debt-to-Equity Ratio0.70 Current Ratio4.05 Quick Ratio4.04 Sales & Book Value Annual Sales$14 million Price / Sales4.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.36 per share Price / Book3.94Miscellaneous Outstanding Shares44,120,000Free Float40,680,000Market Cap$62.65 million OptionableNot Optionable Beta1.75 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Tsontcho Ianchulev M.D. (Age 49)M.P.H., MPH, Co-Founder & Executive Chairman Comp: $920.87kMr. Michael M. Rowe (Age 61)CEO & Director Comp: $750.01kMr. John P. Gandolfo CPA (Age 62)CFO & Secretary Comp: $598.39kMr. Bren Kern (Age 42)COO & Corporate VP Alexander LoboInvestor ContactKey CompetitorsClearside BiomedicalNASDAQ:CLSDTiziana Life SciencesNASDAQ:TLSAAdageneNASDAQ:ADAGKezar Life SciencesNASDAQ:KZRAclaris TherapeuticsNASDAQ:ACRSView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 3,087,021 shares on 11/15/2023Ownership: 8.079%Financial Management Network Inc.Bought 81,250 shares on 10/24/2023Ownership: 0.213%Ellen R StrahlmanBought 4,820 shares on 9/29/2023Total: $8,097.60 ($1.68/share)Michael M RoweBought 1,400 shares on 9/19/2023Total: $2,324.00 ($1.66/share)Michael M RoweBought 1,137 shares on 9/15/2023Total: $1,989.75 ($1.75/share)View All Insider TransactionsView All Institutional Transactions EYEN Stock Analysis - Frequently Asked Questions Should I buy or sell Eyenovia stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" EYEN shares. View EYEN analyst ratings or view top-rated stocks. What is Eyenovia's stock price target for 2024? 3 Wall Street research analysts have issued 12 month price objectives for Eyenovia's shares. Their EYEN share price targets range from $8.00 to $12.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 604.2% from the stock's current price. View analysts price targets for EYEN or view top-rated stocks among Wall Street analysts. How have EYEN shares performed in 2023? Eyenovia's stock was trading at $1.63 at the beginning of 2023. Since then, EYEN stock has decreased by 12.9% and is now trading at $1.42. View the best growth stocks for 2023 here. Are investors shorting Eyenovia? Eyenovia saw a increase in short interest in November. As of November 15th, there was short interest totaling 1,960,000 shares, an increase of 12.0% from the October 31st total of 1,750,000 shares. Based on an average daily volume of 266,200 shares, the days-to-cover ratio is currently 7.4 days. View Eyenovia's Short Interest. When is Eyenovia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our EYEN earnings forecast. How were Eyenovia's earnings last quarter? Eyenovia, Inc. (NASDAQ:EYEN) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. During the same quarter in the prior year, the company earned ($0.23) earnings per share. What other stocks do shareholders of Eyenovia own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eyenovia investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Vaxart (VXRT), Axsome Therapeutics (AXSM), Aldeyra Therapeutics (ALDX), Leap Therapeutics (LPTX), Trevena (TRVN), Albireo Pharma (ALBO), BioXcel Therapeutics (BTAI) and Corvus Pharmaceuticals (CRVS). When did Eyenovia IPO? (EYEN) raised $30 million in an IPO on Thursday, January 25th 2018. The company issued 2,700,000 shares at $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO. Who are Eyenovia's major shareholders? Eyenovia's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (8.08%), Financial Management Network Inc. (0.21%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Bren Kern, Charles E Iv Mather, Ellen R Strahlman, John P Gandolfo, Kenneth B Lee Jr, Michael M Rowe, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev. View institutional ownership trends. How do I buy shares of Eyenovia? Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:EYEN) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eyenovia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.